U.S. Stock News

Cirrus Logic stock has delivered a 51.5% gain over the past three years, yet current checks suggest the shares may still trade below an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach and earnings multiples that both point to undervaluation. Cirrus Logic has returned 51.5% over three years, which puts recent short term pullbacks into the context of a solid medium term gain. Record revenue supported by demand for custom components in smartphones can help underpin...

Geopolitics around the Strait of Hormuz, oil benchmarks like Brent and WTI pushing above key price levels, and higher long term U.S. yields are pulling energy stocks back into focus. That mix can quickly reshape cash flow expectations, debt costs and investor sentiment. This article explains how those forces relate to the Global Energy & Oil Producers screener and identifies 3 stocks that appear most exposed to the latest headlines. The three stocks highlighted below are just a starting...

CareTrust REIT (CTRE) drew investor attention after updating its 2026 net income guidance to approximately $1.53 to $1.56 per share and reporting higher second quarter and first half earnings on August 6, 2026. See our latest analysis for CareTrust REIT. CareTrust REIT's guidance update and solid first half figures come after a mixed stretch for the stock, with the share price down 8.44% over 30 days but still showing an 8.12% year to date share price return and a 1 year total shareholder...

Ascendis Pharma (NasdaqGS:ASND) reported new positive Phase 2 COACH Trial data for TransCon CNP and TransCon hGH combination therapy in children with achondroplasia, along with Week 104 results from the ApproaCH Trial. The company highlighted durable proportional growth effects and a favorable safety profile in the combination regimen based on these trial updates. Ascendis Pharma also completed enrollment in the pivotal reACHin Trial, marking a key step toward potential regulatory...

State Street (STT) has moved to refine its capital structure, filing amendments in Massachusetts to define its new Series L preferred stock after completing a $500 million offering of callable, non cumulative, perpetual depositary shares. See our latest analysis for State Street. The preferred offering and related amendments come at a time when State Street’s share price has moved firmly higher, with a 90 day share price return of 27.94% and a 1 year total shareholder return of 78.08%, which...

Recent commentary on Kohl's (KSS) is driven by ongoing weakness in same-store sales, compressed operating margins, and a high net debt to EBITDA ratio, which raises questions about financial flexibility and potential dilution risk. See our latest analysis for Kohl's. The recent 90 day share price return of 64.22% contrasts with a year to date share price decline of 9.65%. The 1 year total shareholder return of 45.74% sits against a 5 year total shareholder return decline of 54.78%, suggesting...

Abbott Laboratories stock has declined 13.3% over the past year, yet the current valuation checks send a mixed message, because the Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside while market based multiples suggest the share price is roughly in line with peers. Over the last 12 months the share price is down 13.3%, which invites a closer look at whether recent weakness already reflects the key risks in Abbott Laboratories. Recent product momentum around its...

Lightwave Logic, Inc. reported its second-quarter 2026 results, with sales of US$32,751 versus US$25,605 a year earlier and a wider net loss of US$6.61 million compared with US$4.97 million. While revenue in the quarter and year-to-date edged higher, the company’s net losses and loss per share continued to expand, sharpening investor focus on its path toward commercialization. We’ll now examine how Lightwave Logic’s widening net loss, despite incremental sales growth, shapes the company’s...

In recent days, Kupando Therapeutics announced a collaboration using Natera’s Latitude tissue-free MRD assay to monitor ctDNA dynamics in a Phase 1 trial of its KUP-101 immunotherapy across advanced skin cancers, while Natera also reported higher second-quarter 2026 revenue of US$752.75 million and a reduced net loss of US$66.97 million versus a year earlier. These developments, alongside Natera’s raised 2026 revenue guidance, PMDA submission for Signatera in muscle-invasive bladder cancer,...

ITT Inc. recently reported past second-quarter and six-month 2026 results, with sales rising to US$1,473.1 million and US$2,685.0 million respectively, while net income and earnings per share from continuing operations declined compared with the prior year. Alongside these mixed results, ITT raised its full-year 2026 earnings guidance to US$4.47–US$4.67 per share and affirmed its quarterly dividend of US$0.386, signaling management confidence despite acquisition-related pressure on...

Coca-Cola stock has delivered a 78.7% return over the past five years, yet current checks suggest it now trades close to an intrinsic value estimate from a Discounted Cash Flow (DCF) model rather than at a clear bargain. A 78.7% five year return highlights that much of the easy upside may already be reflected in Coca-Cola's share price. Upgraded market expectations around revenue growth and margins can support the valuation, while any setback in those expectations may weigh on how much...

AGNC Investment (AGNC) recently affirmed its income focus with a cash dividend declaration of $0.12 per common share for August 2026. The dividend is payable on September 10 to stockholders of record on August 31. See our latest analysis for AGNC Investment. At a share price of $10.95, AGNC Investment has experienced softer short term share price momentum over the past month, while its 1 year total shareholder return of 31.04% and 3 year total shareholder return of 78.98% indicate a stronger...

In August 2026, OSI Systems, Inc. reported a series of Security division wins, including a five-year IDIQ contract with a ceiling of approximately US$200 million from U.S. Customs and Border Protection for relocatable Rapiscan passenger vehicle inspection systems, alongside separate orders of about US$11 million each from North American and international customers and more than US$10 million for Optoelectronics sub-assemblies. These contract awards, combined with analysts’ expectations for...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Rocket Companies has delivered a strong 3 year share price gain while current valuation checks point to a stock that is closer to fairly priced than clearly cheap, with the Excess Returns intrinsic value estimate and earnings multiples both suggesting limited obvious mispricing. Rocket Companies is up roughly 50% over 3 years, which puts recent share performance well ahead of its shorter term returns and means many earlier buyers are already sitting on gains. Recent profit recovery supported...

Activist investor targets Hilton Grand Vacations board Hilton Grand Vacations (HGV) is in focus after CAS Investment Partners disclosed on 14 August 2026 that it has begun engaging with the company over board composition and potential director nominations. See our latest analysis for Hilton Grand Vacations. Hilton Grand Vacations' share price at US$44.92 has slipped over the past month with a 30 day share price return down 10.05%. However, the 1 year total shareholder return of 0.94% shows...

ACCO Brands Corporation ( NYSE:ACCO ) stock is about to trade ex-dividend in 2 days. The ex-dividend date occurs one...

Nucor Corporation has announced in the past that it would invest US$59,000,000 to expand its Vulcraft Indiana facility in St. Joe, adding steel grating production and creating 20 new full-time jobs, as part of a series of Indiana projects that have already added about 300 roles statewide. These Indiana investments, ranging from modernizing sheet mills to new utility infrastructure and insulated panel facilities, underscore Nucor’s focus on expanding product capabilities and reinforcing its...

Earlier this month, Hims & Hers Health faced intensified legal pressure as the FTC, joined by California and Utah authorities, filed a civil enforcement complaint alleging misleading subscription practices and privacy misrepresentations, which was quickly followed by a consumer class action accusing the company of sharing sensitive health data with advertisers without consent. This legal escalation arrives just days after Hims & Hers reported higher quarterly sales of US$753.21 million but...

EyePoint (EYPT) is back in focus after topline data from its pivotal LUGANO Phase 3 trial of DURAVYU in wet age related macular degeneration, raising fresh questions and interest around the stock. See our latest analysis for EyePoint. The LUGANO readout has sharply reset expectations around EyePoint, with the share price down about 73% year to date and the 1 year total shareholder return declining about 57%. This points to fading momentum as investors reassess both execution risk and future...

10x Genomics stock has delivered a very strong 330.8% return over the past year, yet the current valuation checks lean expensive rather than pointing to an obvious bargain. The 330.8% gain over 12 months highlights how quickly expectations have shifted for 10x Genomics, which raises the bar for what the business now needs to deliver. Stronger interest in the Atera spatial biology platform and related partnerships can support higher revenue expectations, while any slowdown in that demand or...

Recent share performance and business snapshot Heritage Financial (HFWA) has attracted attention after a recent move in its share price, with the stock last closing at $29.60 as of August 18, 2026. Investors are weighing this level against the company’s fundamentals and recent returns. The bank, focused on small and medium sized businesses in the United States, reports revenue of $295.079 million and net income of $77.899 million. Over the past year, total return is 31.5432%, while the past...

Microsoft’s Maia 300 AI chip plans put fresh attention on Taiwan Semiconductor Manufacturing Microsoft’s upcoming Maia 300 AI chip, which is expected in September, has put Taiwan Semiconductor Manufacturing (NYSE:TSM) back in focus as investors weigh what long term capacity commitments could mean for the stock. See our latest analysis for Taiwan Semiconductor Manufacturing. At a share price of US$430.97, Taiwan Semiconductor Manufacturing has seen steady momentum, with a 30 day share price...

Covista Inc. recently reported its fourth-quarter and full-year 2026 results, with full-year sales of US$1.95 billion and net income of US$251.57 million, alongside higher basic and diluted earnings per share from continuing operations compared to the prior year. The company also issued revenue guidance of US$2.05 billion to US$2.09 billion for fiscal 2027 and expanded its leadership team by appointing Scott Liles as Chief Strategy and Performance Officer and President, Medical and...